secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001437749-26-013383
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences reports 100% 6-month and 96% 12-month ablation success in nPulse study
--------------------------------------------------------------------------------

- Sustained 100% procedural success at 6 months (95/95 evaluable patients by holter).
- Sustained 96% procedural success at 12 months (51/53 evaluable patients).
- 90% Kaplan-Meier freedom from AF/AFL/AT at one year; low SAE rate of 1.7% (3/177).
- Efficient procedure: left atrial dwell 18.6 min, total procedure 60.2 min, fluoroscopy 9.4 min.
- Data presented at Heart Rhythm 2026 by Dr. Vivek Reddy; 177 patients treated across 7 European sites.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926013383/0001437749-26-013383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926013383/plse20260424_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-013383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer